A Synageva Board Member’s Trusts Bought Shares

Page 1 of 2

Trusts related to Board of Directors member Thomas Tisch purchased about 21,000 shares of Synageva Biopharma Corp (NASDAQ:GEVA) on January 9th at an average price of $47.53 per share. Tisch and these trusts now own about 750,000 shares, but any increased exposure at all to the company is of questionable wisdom. Insiders are already exposed to company-specific events which can hurt them economically, and so for the trust to purchase more shares would likely reflect high confidence that the stock price will increase in the future. This is one explanation for why insider purchases tend to be bullish signals (see our analysis of studies on insider trading). Our database of insider trading filings last recorded purchases related to Tisch in July 2012 at $41.20 per share.

Ken Griffin CITADEL INVESTMENT GROUP

Synageva is a biotech company whose primary product would be used to treat patients with lysosomal acid lipase (LAL) deficiency. Since the company is mostly in the development stage, it has been unprofitable and is expected to show net losses in 2013 as well, but the market’s perception of its potential has carried it to a market capitalization of $1.2 billion. The stock is up 300% since shortly after its initial public offering in July 2011. At the end of September, Synageva had about $230 million in cash and cash equivalents on its balance sheet, as opposed to $14 million in total liabilities and $17 million in cash used in the first nine months of 2012. As a result we wouldn’t be worried about the company’s cash needs for at least a few more years. We would note that the most recent data has 16% of the outstanding shares held short.

Synageva was one of the top stock picks of Baker Brothers Advisors, a healthcare focused fund, at the end of September. According to the fund’s 13F, it had 8.4 million shares in its portfolio at that time- a 12% increase from three months earlier (find more of Baker Brothers’ favorite stocks). Felix Baker, who co-manages the fund, currently serves on Synageva’s Board of Director. However, the rest of the hedge fund community was cool on Synageva: very few other funds reported positions, while billionaires Ken Griffin and Steve Cohen had their hedge funds sell their shares. Check out which stocks Griffin’s Citadel and Cohen’s SAC Capital liked instead.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!